<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04373473</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-20-0316</org_study_id>
    <nct_id>NCT04373473</nct_id>
  </id_info>
  <brief_title>Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis</brief_title>
  <official_title>A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation (PRIM-DJ2727) Administered Orally in Combination With Standard of Care Therapy for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of lyophilized PRIM-DJ2727&#xD;
      capsules given orally in subjects with ulcerative colitis at remission stage. This study will&#xD;
      also include longitudinal analyses of recipient's gut microbiota taxonomy and metagenomics to&#xD;
      determine potential associations with clinical outcomes in context of active FMT or placebo&#xD;
      administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients in remission after administering 12 weeks of PRIM-DJ2727 capsules will be measured by partial Mayo score ≤ 3</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life will be characterized by health-related quality of life score.</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject-reported score in Hospital Anxiety and Depression Scale</measure>
    <time_frame>9 months</time_frame>
    <description>After administering 12 weeks of PRIM-DJ2727</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Adults With Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Patients with UC will receive FMT capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with ulcerative colitis will receive fecal microbiota capsules from 3 healthy donors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with UC will receive placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with ulcerative colitis will receive matching placebo capsules. Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRIM-DJ2727</intervention_name>
    <description>Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727 capsules consists of lyophilized microbiota suspension from well-screened donors. Microbiota from three donors will be combined to make the product.</description>
    <arm_group_label>Patients with UC will receive FMT capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.</description>
    <arm_group_label>Patients with UC will receive placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult ≥18 years of age&#xD;
&#xD;
          2. History of active UC in the past 12 months based on standard clinical, endoscopic, or&#xD;
             histologic criteria.&#xD;
&#xD;
          3. Remission of UC based on clinical grounds (partial Mayo score of ≤2 with each subscore&#xD;
             ≤1), and on stable maintenance therapy.&#xD;
&#xD;
          4. Sexually active male and female subjects of childbearing potential must agree to use&#xD;
             an effective method of birth control during the study.&#xD;
&#xD;
          5. Female subjects of childbearing potential must have a negative urine Qualitative HCG&#xD;
             pregnancy test at enrolment and on the Week 1, Day 1 of the Treatment prior to&#xD;
             administration of study drug.&#xD;
&#xD;
          6. Willing and able to sign an informed consent form and attend all study-related clinic&#xD;
             visits, assessments, and follow-up phone calls.&#xD;
&#xD;
          7. Subject has an attending physician who will provide the non-FMT care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to take multiple capsules orally.&#xD;
&#xD;
          2. Females who are pregnant, breastfeeding, or planning to become pregnant during the&#xD;
             study.&#xD;
&#xD;
          3. Receipt of systemic non-topical antibiotics within 14 days of treatment day 1.&#xD;
&#xD;
          4. Positive results for active HIV, Hepatitis B, or Hepatitis C infections.&#xD;
&#xD;
          5. History of recurrent Clostridium difficile infection or FMT in the past 6-months.&#xD;
&#xD;
          6. History of other active gastrointestinal conditions such as irritable bowel syndrome,&#xD;
             microscopic colitis, celiac disease, short gut syndrome, colostomy, colectomy,&#xD;
             gastrointestinal fistulae or strictures, chronic parasitic infections, diverticulitis&#xD;
             etc.&#xD;
&#xD;
          7. Known history of bile acid diarrhea&#xD;
&#xD;
          8. Compromised immune system (e.g. primary immune disorders or clinical immunosuppression&#xD;
             due to a medical condition or medication e.g. taking oral prednisone &gt;20 mg a day or&#xD;
             prednisone-equivalent)&#xD;
&#xD;
          9. History of active cancer and/or ongoing chemotherapy (superficial non-metastatic&#xD;
             cancers and maintenance chemotherapy are permitted).&#xD;
&#xD;
         10. History of use of an investigational drug within 90 days prior to the screening visit.&#xD;
&#xD;
         11. History of significant uncontrolled systemic disease that in the opinion of the study&#xD;
             investigator could interfere with study participation and/or objectives.&#xD;
&#xD;
         12. Life expectancy of &lt; 1 year.&#xD;
&#xD;
         13. In the opinion of investigator, subject for any reason, should be excluded from the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Herbert DuPont, md</last_name>
    <phone>713 500 6687</phone>
    <email>herbert.l.dupont@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhi-Dong Jiang, Dr.PH</last_name>
    <phone>713 500 9371</phone>
    <email>zhi-dong.jiang@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert L DuPont, MD</last_name>
      <phone>713-500-9366</phone>
      <email>herbert.l.dupont@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Zhi-Dong Jiang, Dr.PH</last_name>
      <phone>713 500 9371</phone>
      <email>zhi-dong.jiang@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Herbert DuPont, MD</investigator_full_name>
    <investigator_title>Professor of Infectious Diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

